Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

AIDS

Volumn 13, Issue 17, 1999, Pages 2349-2359

  Nijhuis, Monique ^a,b,c   Schuurman, Rob ^a   De Jong, Dorien ^a   Erickson, John ^a   Gustchina, Elena ^a   Albert, Jan ^a   Schipper, Pauline ^a   Gulnik, Sergei ^a   Boucher, Charles A B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SAIC FREDERICK INC   (United States)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Evolution; Fitness; HIV; Resistance

Indexed keywords

PROTEINASE; VIRUS ENZYME;

ARTICLE; DRUG RESISTANCE; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; BASE SEQUENCE; DNA PRIMERS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; PHYLOGENY; RITONAVIR; TIME FACTORS; VARIATION (GENETICS); VIRULENCE; VIRUS REPLICATION;

EID: 0032804864     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912030-00006     Document Type: Article

References (56)

1. Domingo E, Escarmis C, Sevilla N, et al. Basic concepts in RNA virus evolution. FASEBJ 1996, 10:859-864.
2. Coffin JM. Genetic diversity and evolution of retroviruses. Curr Top Microbiol Immunol 1992, 176:143-164.
3. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997, 51:151-178.
4. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995, 69:5087-5094.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
6. Wei X, Chosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
7. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markovvitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
8. Piatak Jr M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR [see comments]. Science 1993, 259:1749-1754.
9. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS [see comments]. Nature 1993, 362:359-362.
10. Pantaleo C, Graziosi C, Demarest JF, et aJ. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
11. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-187.
12. Back NKT, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO I 1996. 15:4040-4049.
13. Goudsmit J, de Ronde A, de Rooij E, de Boer R. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and215.;Virol 1997, 71:4479-4484.
14. Goudsmit J, de Ronde A, Ho DD, Perelson AS. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase .J Virol 1996, 70:5662-5664.
15. Eastman PS, Mittler J, Kelso R, et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (norvir) monolherapy. J Virol 1998, 72:5154-5164.
16. Zhang Y-M, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. ; Virol 1997. 71:6662-6670.
17. Zennou V, Mammano F, Paulos S, Mathez D, Clavel F. Loss of viral fitness associated with multiple gag and Gag-Pol processing defects in human immunodeficiency virus Type 1 variants selected for resistance to protease inhibitors in vivo.J Virol 1998, 72:3300-3306.
18. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. I Virol 1998, 72:7632-7637.
19. Markowitz M, Saag M, Powderly VVG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New Engt J Med 1995, 333:1534-1539.
20. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinelics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. New Engl J Med 1995, 333:1528-1533.
21. Molla A, Korneyeva M, Cao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
22. Erickson JW, Burt SK. Structural mechanism of HIV drug resistance. Annu Rev Pharmacol Toxicol 1996, 36:545-571.
23. Rose RB, Craik CS, Stroud RM. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 1998, 37:2607-2621.
24. Boom R, Sol CJA, Salimans MMM, Jansen CL, VVertheim-van Dillen PME, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbhl 1990, 28:495-503.
25. Mulder J, McKinney N, Christopherson C, Sninsky J, Creenfield L, Kvvok S. Rapid and simple PCR assay for quantification of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
26. Nijhuis M, Boucher CAB, Schuurman R. Sensitive procedure for the amplification of HIV-1 RNA using a combined reversetranscription and amplification reaction. Biotechniques 1995, 19:178-180.
27. Culnik S, Suvorov LI, Liu B, et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995, 34:9282-9287.
28. Louis JM, Nashed NT, Parris KD, Kimmel AR, Jerina DM. Kinetics and mechanism of auloprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein. Proc Nail Acad Sei USA 1994, 91:7970-7974.
29. Co E, Koelsch G, Lin Y, Ido E, Hartsuck JA, Tang J. Proteolytic processing mechanisms of a miniprecursor of the aspartic protease of human immunodeficiency virus type 1. Biochemistry 1994, 33:1248-1254.
30. Ermolieff J, Lin X, Tang J. Kinetic properties of saquinavirresistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. Biochemistry 1997, 36:12364-12370.
31. Kageyama S, Mimoto T, Murakawa Y, et al. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Anlimicrob Agents Chemother 1993, 37:810-817.
32. Maschera B, Furfine E, Blair ED. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors.; Virol1995, 69:5431-5436.
33. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg 1983, 493-497.
34. Boucher CAB, Keulen W, van Bommel T, et al. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antim Ag Chemoth 1996, 40:2404-2409.
35. Moore JP, McKeating JA, Weiss RA, Sattentau QJ. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990,250:1139-1142.
36. McKeating J, Balfe P, Clapham P, VVeiss RA. Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.; Virol 1991, 65:4777-4785.
37. Felsenstein J. PHYLIP: Phylogenetic inference package 3.4. Seattle: University of Washington; 1991.
38. Lech WJ, Wang G, Yang YL, et al. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996, 70:2038-2043.
39. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphism observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med 1996, 2:753-759.
40. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
41. de Jong MD, Schuurman R, Lange JMA, Boucher CAB. Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. Antiviral Thier 1996, 1:33-41.
42. Najera I, Holguin A, Quinones-Mateu ME, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995, 69:23-31.
43. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapineresistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Viml 1996, 70:7894-7899.
44. Rose RE, Gong YF, Creytok JA, et al. Human immunodeficiency virus type 1 viral background plays a mojor role in development of resistance to protease inhibitors. Proc Nail Acad Sei USA 1996, 93:1648-1653.
45. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996, 70:3763-3769.
46. Borman AM, Paulos S, Clavel F. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 1996, 77:419-426.
47. Novella IS, Clarke DK, Quer J, et al. Extreme fitness differences in mammalian and insect hosts after continuous replication of vesicular stomatitis virus in sandfly cells. J Virol 1995, 69:6805-6809.
48. Novella IS, Duarte EA, Elena SF, Moya A, Domingo E, Holland JJ. Exponential increases of RNA virus fitness during large population transmissions. Proc Natl Acad Sei USA 1995, 92:5841-5844.
49. Bouma JE, Lenski RE. Evolution of a bacteria/plasmid association. Nature 1988, 335:351-352.
50. Schrag SJ, Perrot V, Levin BR. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc Royal Soc Lend B 1997,264:1287-1291.
51. Lenski RE, Travisano M. Dynamics of adaptation and diversification: A 10,000-generation experiment with bacterial populations. Proc Nail Acad Sei USA 1994, 91:6808-6814.
52. Wright S. The role of mutation, inbreeding, crossbreeding and selection in evolution. Proc VI Intern Cong Genet 1932, 1:356-366.
53. McLean AR, Emery VC, Webster A, Griffiths PD. Population dynamics of HIV within an individual after treatment with zidovudine. AIDS 1991, 5:485-489.
54. de Jong MD, Veenstra J, Stilianakis NI, et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Nail Acad Sei USA 1996, 93:5501-5506.
55. de Boer RJ, Boucher CAB. Anti-CD4 therapy for AIDS suggested by mathematical models. Proc Royal Soc Lond B 1996, 263:899-905.
56. Roos M, Miedema F, Eeftinck Schattenkerk JKM, et al. Cellular and humoral immunity in various cohorts of male homosexuals in relation to infection with human immunodefiency virus. Neth J Med 1989, 34:132-141.